Compare ATLX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7M | 139.3M |
| IPO Year | N/A | 2013 |
| Metric | ATLX | KPTI |
|---|---|---|
| Price | $5.21 | $8.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 635.0K | 315.7K |
| Earning Date | 11-13-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $180,454.00 | ★ $142,530,000.00 |
| Revenue This Year | $22,084.55 | $3.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $3.51 |
| 52 Week High | $8.25 | $11.55 |
| Indicator | ATLX | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 75.48 |
| Support Level | $4.77 | $7.01 |
| Resistance Level | $5.33 | $7.44 |
| Average True Range (ATR) | 0.36 | 0.47 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 91.00 | 84.26 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project located in Minas Gerais State in Brazil. The company intends to produce and sell lithium concentrate, a key ingredient for the battery supply chain. It intends to mine and then process its lithium-containing ore to produce lithium concentrate (also known as spodumene concentrate), a key ingredient for the battery supply chain.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.